NORWELL, Mass. — The National Organization for Rare Disorders (NORD®) has issued a strong statement of support for the U.S. Food and Drug Administration (FDA) following the agency’s announcement that it is launching a major initiative to develop a new regulatory framework specifically tailored to the scientific and practical hurdles inherent in rare disease drug development and review.
The statement, released by Pam Gavin, President and Chief Executive Officer of NORD, marks a significant moment for the millions of individuals and families affected by rare conditions. According to the organization, this policy shift represents a crucial and long-awaited step forward for the rare disease community as a whole.
In her statement, Gavin congratulated FDA leadership for recognizing that extraordinary scientific advances in the understanding of rare diseases must be matched by a corresponding evolution in how potential therapies are evaluated and regulated. NORD highlighted that the initiative is a direct and encouraging response to the urgent needs expressed by the rare disease community, noting specifically the concerns that NORD and other patient advocacy organizations brought directly to the Acting Commissioner during meetings held in June. For patients and their families who have endured years—and in some cases, generations—without viable treatment options, this formal commitment by the regulatory agency offers meaningful and tangible hope for future medical progress.
To fully understand the gravity of this new initiative, NORD reflected on its historical context. Since its founding in 1983, the organization has consistently championed public policies designed to accelerate rare disease research and therapeutic development. That same landmark year, the passage of the Orphan Drug Act fundamentally transformed the global landscape of rare disease innovation by establishing critical financial and regulatory incentives to encourage the development of treatments for conditions that had long been overlooked by mainstream commercial drug developers.
Now, more than four decades later, exponential leaps in scientific discovery have created unprecedented opportunities for medical breakthroughs. However, this scientific progress has simultaneously underscored an urgent institutional need: a regulatory framework that keeps pace with modern innovation while effectively addressing the distinct and often complex challenges associated with rare diseases.
Traditional approaches to clinical drug development, which were often built around large-scale common diseases, frequently fall short when applied to rare conditions. Obstacles such as small patient populations, limited natural history data, high levels of disease heterogeneity, and the frequent absence of established biomarkers or standardized clinical endpoints can make traditional clinical trial designs extraordinarily difficult—and in some cases entirely infeasible.
NORD emphasized that establishing a modern regulatory framework that consistently accounts for these real-world realities, while simultaneously maintaining rigorous standards for drug safety and effectiveness, is an absolute prerequisite to translating laboratory discoveries into accessible, life-changing treatments.
Within the broader scope of the initiative, NORD specifically welcomed several key focal points prioritized by the FDA. These include strengthening consistency and predictability across the agency’s various review divisions, systematically incorporating patient perspectives throughout both the development and review cycles, drawing upon external scientific and clinical expertise when necessary, and building the deep institutional knowledge required to support sound, forward-looking regulatory decision-making. At the same time, NORD noted that sustained leadership, adequate institutional staffing and resources, and consistent implementation across every level of the agency will be essential to ensure the initiative succeeds.
What elevates the importance of this new initiative, according to NORD, is the unique opportunity it provides to move beyond ad-hoc, case-by-case regulatory accommodations. Instead, the agency is aiming to build a comprehensive framework designed from the ground up around the genuine scientific realities of rare conditions. When traditional clinical trial methodologies are simply not practical or possible, the medical and regulatory ecosystems require scientifically rigorous, validated ways to evaluate alternative forms of evidence. NORD stressed that this regulatory evolution is not about lowering safety or efficacy standards. Rather, it is fundamentally about ensuring that the methods used to demonstrate those standards are entirely appropriate for the specific, unique diseases and experimental treatments under evaluation.
Looking ahead, NORD stated that it looks forward to actively participating in the FDA’s upcoming stakeholder engagement process. The organization intends to work closely alongside both the agency and the wider rare disease community to help shape the trajectory and implementation of this important initiative.
Furthermore, NORD announced that it eagerly anticipates welcoming key FDA leadership—including the Acting Commissioner and representatives from the FDA’s specialized Rare Disease Innovation Hub—to the upcoming 2026 Rare Diseases and Orphan Products Breakthrough Summit®. The conference is scheduled to take place from October 25 to October 27 in Washington, D.C. According to the organization, the annual summit will provide a timely, critical early opportunity for the rare disease community to engage in direct dialogue with top FDA leadership, allowing stakeholders to explore the new framework and its broad implications in much greater detail.
Ultimately, NORD underscored that the true measure of success for this initiative will not be found in policy announcements alone, but in whether this high-level commitment successfully translates into more consistent regulatory practices, more efficient and effective pathways for developing therapies, and, most importantly, a tangible increase in approved treatment options for people living with rare diseases.
As the process moves forward, NORD affirmed that it stands fully prepared to work side-by-side with the FDA and the broader rare disease community. The shared goal remains turning this institutional commitment into meaningful, real-world progress—and ultimately delivering the safe and effective treatments that millions of individuals and families are counting on.
